stella
beta
Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC — Stella
Recruiting
Back to Potentially Resectable Stage II/IIIa NSCLC trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
South Korea
Severance Hospital, Seoul
View full record on ClinicalTrials.gov